The mRNA-1273-P203 clinical trial is evaluating an investigational vaccine that may protect adolescents between the ages of 12–17 from getting COVID-19 if they come in contact with the SARS-COV-2 virus. Both the two-dose initial investigational vaccine series and the investigational third dose are being evaluated in this clinical trial.
A vaccine that prevents COVID-19 disease and SARS-CoV-2 transmission in adolescents would be a crucial public health tool to help curb the pandemic.
The purpose of this study is to seek an indication for use of the mRNA-1273 vaccine in adolescents of 12–17 years old. Volunteers will participate and be followed by medical staff for up to 25 months.
Sites are located in the cities/states identified with the red pin:
The clinical trial doctor and medical staff will talk to you and your child about additional medical support that your child will receive if they experience COVID-19 symptoms at any time while in this clinical trial. Insurance is not needed to join this clinical trial, and compensation for your time may be available.